Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon
ACC.24 sign American College of Cardiology

ACC.24: Impella CP boosts survival for patients with STEMI-related cardiogenic shock

“This is the first time in a very long time that we have a positive study for managing cardiogenic shock,” one cardiologist said. 

ACC.24 late-breaking clinical trials

ACC.24: Self-expanding Evolut valves offer superior performance for TAVR patients with small annuli

The SMART trial included one-year data from TAVR patients randomized to receive either a self-expanding Evolut valve or a balloon-expandable Sapien 3 valve. All patients presented with symptomatic severe aortic stenosis and a small aortic annulus. A whopping 87% of participants were women. 

semaglutide wegovy Novo Nordisk major adverse cardiovascular events

Weight loss drug semaglutide benefits obese patients presenting with HFpEF, type 2 diabetes

The new research, based on data from more than 600 patients, was presented at ACC.24 in Atlanta and published in the New England Journal of Medicine. Semaglutide is sold by Novo Nordisk under the brand name Wegovy.

ACC.24, the annual meeting of the American College of Cardiology (ACC), kicked off on Saturday, April 6, with a series of late-breaking clinical trials focused on testing the safety and effectiveness of new treatment strategies.

Day 1 at ACC.24: Late-breakers examine potential new heart attack, heart failure treatments

ACC.24 in Atlanta began Saturday, April 6, with a series of late-breaking clinical trials exploring brand new treatment strategies. 

healthcare value value-based care money dollar

Johnson & Johnson to acquire Shockwave Medical for $13.1B

The rumors, it seems, were true. Once the deal is finalized, Shockwave Medical will operate as a business unit within Johnson & Johnson MedTech.

Transcatheter pulmonary valve replacement (TPVR) with Medtronic’s self-expanding Harmony valve is both safe and effective after more than a year, according to new real-world data published in the Journal of the American College of Cardiology.[1]

TPVR with self-expanding Harmony valve associated with ‘excellent’ real-world outcomes

Transcatheter pulmonary valve replacement is still linked to certain risks, researchers noted, but new data confirm it is a safe, effective treatment option for patients with severe PR. 

Osso VR, a San Francisco-based virtual reality (VR) company, has developed a new VR training simulation focused on left atrial appendage occlusion (LAAO) procedures. The simulation is designed to offer clinicians a new way to practice LAAO procedures in a “repeatable, risk-free virtual environment.”

Cardiologist-approved VR for interventional procedures headed to ACC.24

San Francisco-based Osso VR and the American College of Cardiology have collaborated on advanced LAAO simulations. The two groups first started working together back in 2022. 

FDA announces new recall of neurovascular catheters built by Johnson & Johnson subsidiary

The recall is due to ongoing concerns about the devices breaking. Three patients have been injured as a result of this issue.

Displaying 689 - 696 of 10940

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.